Login

Nadia Haj Mohammad

ORCID: 0000-0002-4688-2921
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5086553242
Research Areas
  • Esophageal Cancer Research and Treatment
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Esophageal and GI Pathology
  • Gastrointestinal Tumor Research and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Neuroendocrine Tumor Research Advances
  • Metastasis and carcinoma case studies
  • Cancer Genomics and Diagnostics
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Pancreatitis Pathology and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Renal cell carcinoma treatment
  • Gallbladder and Bile Duct Disorders
  • Lung Cancer Treatments and Mutations
  • Multiple and Secondary Primary Cancers
  • Colorectal Cancer Treatments and Studies
  • Advanced MRI Techniques and Applications
  • Radiomics and Machine Learning in Medical Imaging
  • Head and Neck Cancer Studies
  • MRI in cancer diagnosis
  • Advanced NMR Techniques and Applications
  • Cancer Treatment and Pharmacology
  • Cancer Diagnosis and Treatment
  • Colorectal and Anal Carcinomas

University Medical Center Utrecht
 2016-2025

Utrecht University
 2018-2025

St. Antonius Ziekenhuis
 2019-2024

University Hospital Heidelberg
 2017-2022

Heidelberg University
 2017-2022

Netherlands Comprehensive Cancer Organisation
 2020-2021

Umenz (Netherlands)
 2021

Amsterdam UMC Location University of Amsterdam
 2014-2020

Amsterdam University Medical Centers
 2020

Vrije Universiteit Amsterdam
 2020

 Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer
OPENALEX - Publications 
Pieter C. van der Sluis Sylvia van der Horst Anne M. May Carlo Schippers Lodewijk A.A. Brosens and 8 more Hans C. A. Joore Christiaan Kroese Nadia Haj Mohammad Stella Mook Frank P. Vleggaar Inne H.M. Borel Rinkes Jelle P. Ruurda Richard van Hillegersberg

The standard curative treatment for patients with esophageal cancer is perioperative chemotherapy or preoperative chemoradiotherapy followed by open transthoracic esophagectomy (OTE). Robot-assisted minimally invasive thoracolaparoscopic (RAMIE) may reduce complications.A single-center randomized controlled trial was conducted, assigning 112 resectable intrathoracic to either RAMIE OTE. primary endpoint the occurrence of overall surgery-related postoperative complications (modified...

10.1097/sla.0000000000003031 article EN Annals of Surgery 2018-10-11
 Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
OPENALEX - Publications 
Jony van Hilst Thijs de Rooij K. Bosscha David J. Brinkman Susan van Dieren and 95 more Marcel G. W. Dijkgraaf Michael F. Gerhards Ignace H. J. T. de Hingh Tom M. Karsten Daniel J. Lips Misha Luyer Olivier R. Busch Sebastiaan Festen Marc G. Besselink Jony van Hilst Thijs de Rooij K. Bosscha David J. Brinkman Susan van Dieren Marcel G. W. Dijkgraaf Michael F. Gerhards Ignace H. J. T. de Hingh Tom M. Karsten Daniel J. Lips Misha Luyer Olivier R. Busch Sebastiaan Festen Marc G. Besselink Hendrik A. Marsman Thomas M. van Gulik Dennis A. Wicherts Wietse J. Eshuis Luna A. Stibbe Els J. Nieveen van Dijkum Janine E Van Hooft Paul Fockens Hanneke W.M. van Laarhoven Johanna W. Wilmink Marcel J Van de Vijver Maarten F. Bijlsma Joanne Verheij C. Yung Nio Krijn P. van Lienden Geertjan van Tienhoven Annuska Schoorlemmer Geert-Jan Creemers Casper HJ van Eijck Bas Groot Koerkamp Marco J. Bruno Ferry A.L.M. Eskens Joost J. Nuyttens Chulja J. Pek George P. van der Schelling Tom Seerden Gijs A. Patijn Vincent B. Nieuwenhuijs Jan Willem de Groot Bert A. Bonsing Alexander L. Vahrmeijer Rutger‐Jan Swijnenburg J. Sven D. Mieog Erwin van der Harst Marcel den Dulk Steven W.M. Olde Damink C. Dejong Ronald M. van Dam Judith MPGM De Vos Mike S.L. Liem Cees J. van Laarhoven Harry van Goor Peter B. van den Boezem B M van der Kolk Martijn W.J. Stommel John J. Hermans Erwin JM van Geenen Sandra A. Radema Lodewijk A.A. Brosens Joris J. Scheepers Daphne Roos Djamilla Boerma Wouter te Riele Hjalmar C. van Santvoort Thomas L. Bollen Fanny Wit I. Quintus Molenaar Nadia Haj Mohammad Maarten S. van Leeuwen Annemarie Roele Kees P De Jong Vincent E. de Meijer Joost M. Klaase Geert Kazemier Babs M. Zonderhuis Freek Daams Martijn R. Meijerink Anouk E.J. Latenstein L. Bengt van Rijssen Carolijn L. Nota Emo van Halsema Eran van Veldhuisen

10.1016/s2468-1253(19)30004-4 article EN ˜The œLancet. Gastroenterology & hepatology 2019-01-27
 Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
OPENALEX - Publications 
Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S. Finn Junji Furuse and 95 more Zhenggang Ren Thomas Yau Heinz‐Josef Klümpen Stephen L. Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W. Valle Li Yu Usha Malhotra Abby B. Siegel Julien Edeline Arndt Vogel Mehmet Akce Inmaculada Alés Díaz Gustavo R. Alves Sumitra Anand Çağatay Arslan Jamil Asselah Éric Assenat F. Aubin Li‐Yuan Bai Yuxian Bai Olga Barajas Susan E. Bates Stephen Begbie Irit Ben‐Aharon Nina Beri Marie‐Luise Berres Jean‐Frédéric Blanc Ivan Borbath Robert Bordonaro Mohamed Bouattour Giovanni Brandi Adam M. Burgoyne Kritiya Butthongkomvong Marcos Pedro Guedes Camandaroba Ke Cao Marcela Carballido Stephen L. Chan Jen‐Shi Chen Ming‐Huang Chen Xiaohong Chen Ashley Cheng Tai‐Jan Chiu Hye Jin Choi Hong Jae Chon Joëlle Collignon Antonio Cubillo Gracián S. Lindsey Davis Ricardo Saraiva de Carvalho D.J.A. de Groot Anne Demols Judith De Vos Maria Diab Jacob C. Easaw Martin Eatock Julien Edeline Rawad Elias Fredericus Eskens Alfredo Falcone Plinio Fernández Richard S. Finn Fábio Franke Masayuki Furukawa Junji Furuse Olumide B. Gbolahan Karen Geboes Keri-Lee Geneser Zhimin Geng Ravit Geva Roopinder Gillmore Thorsten Oliver Goetze Hongfeng Gou Julieta Grasselli Shanzhi Gu Mahmut Gümüş Nadia Haj Mohammad Chunyi Hao Hakan Harputluoğlu Hassan Hatoum Volker Heinemann Wang Kwong Ho Chiun Hsu Ayala Hubert Jun‐Eul Hwang Mevlüde İnanç Soledad Iseas Vaishnavi Jeyasingam Paula Jiménez Fonseca Warren Joubert Jitlada Juengsamarn

10.1016/s0140-6736(23)00727-4 article EN The Lancet 2023-04-16
 Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study
OPENALEX - Publications 
Bo Jan Noordman Manon C.W. Spaander Roelf Valkema Bas P. L. Wijnhoven Mark I. van Berge Henegouwen and 40 more Joël Shapiro Katharina Biermann Ate van der Gaast Richard van Hillegersberg Maarten C.C.M. Hulshof Kausilia K. Krishnadath Sjoerd M. Lagarde Grard A. P. Nieuwenhuijzen Liekele E. Oostenbrug Peter D. Siersema Erik J. Schoon Meindert N. Sosef Ewout W. Steyerberg J. Jan B. van Lanschot Michael Doukas Nanda C. Krak Jan‐Werner Poley Caroline M. van Rij Jaques J.G.H.M. Bergman Suzanne S. Gisbertz Hanneke WM van Laarhoven Sybren L. Meijer Lucas Goense Nadia Haj Mohammad Monique G.G. Hobbelink G. J. A. Offerhaus Frank P. Vleggaar Wouter L. Curvers Geert‐Jan Creemers Mark J. Roef Maurice J.C. van der Sangen Jeroen Buijsen Robert G. Riedl Wendy Schreurs Fabienne Warmerdam MJR Janssen Chella van der Post Sandra A. Radema Camiel Rosman Heidi Rütten

10.1016/s1470-2045(18)30201-8 article EN The Lancet Oncology 2018-06-01
 Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
OPENALEX - Publications 
Tom van den Ende Nicolien C. de Clercq Mark I. van Berge Henegouwen Suzanne S. Gisbertz Elisabeth D. Geijsen and 17 more Rob H.A. Verhoeven Sybren L. Meijer Sandor Schokker Mark P.G. Dings Jacques Bergman Nadia Haj Mohammad Jelle P. Ruurda Richard van Hillegersberg Stella Mook Max Nieuwdorp Tanja D. de Gruijl Tanya T.D. Soeratram Bauke Ylstra Nicole C.T. van Grieken Maarten F. Bijlsma Maarten C.C.M. Hulshof Hanneke W.M. van Laarhoven

The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated feasibility and efficacy of nCRT combined programmed-death ligand-1 (PD-L1) inhibition rEAC.Patients rEAC received according to regimen five cycles atezolizumab (1,200 mg). primary endpoint was administering in ≥75% patients. A propensity score-matched cohort used compare pathologic response, overall survival, progression-free...

10.1158/1078-0432.ccr-20-4443 article EN Clinical Cancer Research 2021-01-27
 European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
OPENALEX - Publications 
Tiuri E. Kroese Sebastiaan F. C. Bronzwaer Peter S.N. van Rossum Sebastian F. Schoppman Pieter Deseyne and 67 more Eric Van Cutsem Karin Haustermans Philippe Nafteux Mélissa Thomas Radka Obermannová H.R. Mortensen Marianne Nordsmark Per Pfeiffer Anneli Elme Antoine Adenis Guillaume Piessen Christiane J. Bruns Florian Lordick Ines Gockel Markus Moehler Cihan Gani Theodore Liakakos John V. Reynolds A.G. Morganti Riccardo Rosati Carlo Castoro Francesco Cellini Domenico D’Ugo Franco Roviello Maria Bencivenga Giovanni de Manzoni Mark I. van Berge Henegouwen M Hulshoff Jolanda van Dieren Marieke A. Vollebergh Johanna W. van Sandick Paul M. Jeene C.T. Muijs Marije Slingerland Francine E.M. Voncken Henk H. Hartgrink Geert-Jan Creemers Maurice J.C. van der Sangen Grard A. P. Nieuwenhuijzen Maaike Berbée Marcel Verheij Bas P. L. Wijnhoven Laurens V. Beerepoot Nadia Haj Mohammad Stella Mook Jelle P. Ruurda Piotr Kołodziejczyk Wojciech Polkowski Lucjan Wyrwicz María Alsina Josep Tabernero Manuel Pera Tania Fleitas Andrés Cervantes Magnus Nilsson Stefan Mönig Dorothea Wagner Matthias Gückenberger Ewen A. Griffiths Elizabeth Smyth George B. Hanna Sheraz R. Markar M. Asif Chaudry M. Hawkins Edward Cheong Hanneke W.M. van Laarhoven Richard van Hillegersberg

The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD).

10.1016/j.ejca.2024.114062 article EN cc-by European Journal of Cancer 2024-04-17
 Heart rate dependency of pulse pressure amplification and arterial stiffness
OPENALEX - Publications 
Ian B. Wilkinson Nadia Haj Mohammad S. Tyrrell I.R. Hall David J. Webb and 3 more В. Paul Terry Levy John Cockcroft

Background:Pulse pressure and aortic pulse wave velocity, measures of arterial stiffness, are both important determinants cardiovascular risk. However, assessment peripheral does not always provide a reliable measure changes in central or stiffness. The aim the present study was to assess effect acute heart rate on stiffness healthy subjects.

10.1016/s0895-7061(01)02252-x article EN American Journal of Hypertension 2002-01-01
 Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma
OPENALEX - Publications 
Anouk E.J. Latenstein Lydia G. van der Geest Bert A. Bonsing Bas Groot Koerkamp Nadia Haj Mohammad and 13 more Ignace H. J. T. de Hingh Vincent E. de Meijer I. Quintus Molenaar Hjalmar C. van Santvoort Geertjan van Tienhoven Joanne Verheij Pauline A. J. Vissers Judith de Vos‐Geelen Olivier R. Busch Casper H.J. van Eijck Hanneke W.M. van Laarhoven Marc G. Besselink Johanna W. Wilmink

BackgroundIn recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate trends incidence, survival of PDAC.Materials methodsPatients with PDAC (1997–2016) were included from the Netherlands Cancer Registry. Results categorised by period diagnosis (1997–2000,...

10.1016/j.ejca.2019.11.002 article EN cc-by-nc-nd European Journal of Cancer 2019-12-13
 Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)
OPENALEX - Publications 
Koen P. Rovers Checca Bakkers Geert A. Simkens Jacobus W. A. Burger Simon W. Nienhuijs and 54 more Geert-Jan Creemers Anna M.J. Thijs Alexandra R. M. Brandt‐Kerkhof Eva V. E. Madsen Ninos Ayez Nadine L. de Boer Esther van Meerten Jurriaan B. Tuynman Miranda Kusters Nina R. Sluiter Henk M.W. Verheul Hans van Vliet Marinus J. Wiezer Djamila Boerma Emma C. E. Wassenaar Maartje Los Cornelis B. Hunting Arend G. J. Aalbers Niels F.M. Kok Koert F.D. Kuhlmann Henk Boot Myriam Chalabi Schelto Kruijff Lukas B. Been Robert J. van Ginkel Derk Jan A. de Groot Rudolf S.N. Fehrmann Johannes H.W. de Wilt Andreas J. A. Bremers Philip R. de Reuver Sandra A. Radema Karin H. Herbschleb Wilhelmina M. U. van Grevenstein Arjen J. Witkamp Miriam Koopman Nadia Haj Mohammad Eino B. van Duyn W. J. B. Mastboom Leonie J. Mekenkamp Joost Nederend Max J. Lahaye Pétur Snæbjörnsson Cornelis Verhoef Hanneke W.M. van Laarhoven Aeilko H. Zwinderman Jeanette M. Bouma Onno Kranenburg Iris van ’t Erve Remond J.A. Fijneman Marcel G. W. Dijkgraaf Patrick Hemmer Cornelis J.A. Punt Pieter J. Tanis Ignace H. J. T. de Hingh

Abstract Background Upfront cytoreductive surgery with HIPEC (CRS-HIPEC) is the standard treatment for isolated resectable colorectal peritoneal metastases (PM) in Netherlands. This study investigates whether addition of perioperative systemic therapy to CRS-HIPEC improves oncological outcomes. Methods open-label, parallel-group, phase II-III, randomised, superiority performed nine Dutch tertiary referral centres. Eligible patients are adults who have a good performance status,...

10.1186/s12885-019-5545-0 article EN cc-by BMC Cancer 2019-04-25
 Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study
OPENALEX - Publications 
Marin Strijker Ali Belkouz Lydia G. van der Geest Thomas M. van Gulik Jeanin E. van Hooft and 9 more Vincent E. de Meijer Nadia Haj Mohammad Philip R. de Reuver Joanne Verheij Judith de Vos‐Geelen Johanna W. Wilmink Bas Groot Koerkamp Heinz‐Josef Klümpen Marc G. Besselink

Background: Population-based data on distal cholangiocarcinoma (DCC) from the Western world are not available, albeit essential to identify areas for improvement. This study investigated incidence, treatment and outcomes, including time trends predictors survival, in a nationwide cohort of DCC. Methods: is retrospective patients diagnosed with DCC (2009-2016) derived Netherlands Cancer Registry. Overall survival (OS) its were analyzed using Kaplan-Meier Cox regression analysis. Time...

10.1080/0284186x.2019.1590634 article EN cc-by-nc-nd Acta Oncologica 2019-03-25
 The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis
OPENALEX - Publications 
Tara M. Mackay F. Jasmijn Smits Daphne Roos Bert A. Bonsing K. Bosscha and 25 more Olivier R. Busch Geert‐Jan Creemers Ronald M. van Dam Casper H.J. van Eijck Michael F. Gerhards Jan Willem B. de Groot Bas Groot Koerkamp Nadia Haj Mohammad Erwin van der Harst Ignace H. J. T. de Hingh Marjolein Y.V. Homs Geert Kazemier Mike S.L. Liem Vincent E. de Meijer I. Quintus Molenaar Vincent B. Nieuwenhuijs Hjalmar C. van Santvoort George P. van der Schelling Martijn W.J. Stommel Albert J. ten Tije Judith de Vos‐Geelen Fennie Wit Johanna W. Wilmink Hanneke W.M. van Laarhoven Marc G. Besselink

10.1016/j.hpb.2019.06.019 article EN publisher-specific-oa HPB 2019-08-19
 Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent
OPENALEX - Publications 
Kevin Parry Els Visser Peter S.N. van Rossum Nadia Haj Mohammad Jelle P. Ruurda and 1 more Richard van Hillegersberg

Strategies for the treatment of recurrence after initial curative esophagectomy are increasingly being recognized. The aim this study was to identify prognostic factors that affect survival in patients with and evaluate strategies.A prospective database (2003-2013) used collect consecutive esophageal carcinoma treated esophagectomy. Locations, symptoms, were registered. Post-recurrence defined as time between first death or last follow-up.Of 335 selected patients, 171 (51 %) developed...

10.1245/s10434-015-4840-5 article EN cc-by Annals of Surgical Oncology 2015-09-02
 Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study
OPENALEX - Publications 
I. Mokadem Willemieke P.M. Dijksterhuis Margreet van Putten Lianne Heuthorst Judith de Vos‐Geelen and 4 more Nadia Haj Mohammad Grard A. P. Nieuwenhuijzen Hanneke W.M. van Laarhoven Rob H.A. Verhoeven

In most western European countries perioperative chemotherapy is a part of standard curative treatment for gastric cancer. Nevertheless, recurrence rates remain high after multimodality treatment. This study examines patterns in patients receiving with surgery cancer real-world setting. All diagnosed adenocarcinoma between 2010 and 2015 who underwent at least preoperative gastrectomy intent (cT1N+/cT2-4a,X; any cN; cM0) 18 Dutch hospitals were selected from the Netherlands Cancer Registry....

10.1007/s10120-019-00956-6 article EN cc-by Gastric Cancer 2019-04-04
 Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: A randomized controlled trial.
OPENALEX - Publications 
Pieter C. van der Sluis Sylvia van der Horst Anne M. May Carlo Schippers Lodewijk A.A. Brosens and 9 more Wouter van Dijk Hans C. A. Joore Christiaan Kroese Nadia Haj Mohammad Stella Mook Frank P. Vleggaar Inne Borel Rinkes Jelle P. Ruurda Richard van Hillegersberg

6 Background: The standard curative treatment for patients with esophageal cancer is perioperative chemotherapy or preoperative chemoradiotherapy followed by open transthoracic esophagectomy (OTE). Robot-assisted minimally invasive thoraco-laparoscopic (RAMIE) may reduce complications and improve functional recovery. Methods: In this randomized controlled trial, 112 resectable intrathoracic were randomly assigned to RAMIE OTE. composite primary endpoint was the occurrence of overall...

10.1200/jco.2018.36.4_suppl.6 article EN Journal of Clinical Oncology 2018-02-01
 18F-Fludeoxyglucose–Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer
OPENALEX - Publications 
Emma C. Gertsen Hylke J.F. Brenkman Richard van Hillegersberg Johanna W. van Sandick Mark I. van Berge Henegouwen and 48 more Suzanne S. Gisbertz Misha Luyer Grard A. P. Nieuwenhuijzen J. Jan B. van Lanschot Sjoerd M. Lagarde Bas P. L. Wijnhoven Wobbe O. de Steur Henk H. Hartgrink Jan H.M.B. Stoot Karel W. E. Hulsewé Ernst Jan Spillenaar Bilgen Marc J. van Det Ewout A. Kouwenhoven Donald L. van der Peet Freek Daams Nicole C.T. van Grieken Joos Heisterkamp Boudewijn van Etten Jan Willem van den Berg Jean-Pierre E. N. Pierie Hasan H. Eker Annemieke Y. Thijssen Eric J.T. Belt Peter van Duijvendijk Eelco B. Wassenaar Hanneke W.M. van Laarhoven Kevin P. Wevers Lieke Hol Frank J. Wessels Nadia Haj Mohammad Miriam P. van der Meulen Geert Frederix Erik Vegt Peter D. Siersema Jelle P. Ruurda Jessy Joy van Kleef Mariska J Prins Joyce Pijpers Jerôme Profar Stan Tummers Kees de Mooij Maaike van Dam Monique Heijmans Antoinette van Groenestyn Edith Bouwmeester Ilse Masselink Damiana Beumer Nel de Vries

<h3>Importance</h3> The optimal staging for gastric cancer remains a matter of debate. <h3>Objective</h3> To evaluate the value of<sup>18</sup>F-fludeoxyglucose–positron emission tomography with computed (FDG-PET/CT) and laparoscopy (SL) in addition to initial by means gastroscopy CT patients locally advanced cancer. <h3>Design, Setting, Participants</h3> This multicenter prospective, observational cohort study included 394 advanced, clinically curable adenocarcinoma (≥cT3 and/or N+, M0...

10.1001/jamasurg.2021.5340 article EN JAMA Surgery 2021-10-27
 Nationwide treatment and outcomes of perihilar cholangiocarcinoma
OPENALEX - Publications 
Anne‐Marleen van Keulen Stijn Franssen Lydia G. van der Geest Marieke T. de Boer Minneke J. Coenraad and 10 more Lydi M.J.W. van Driel Joris I. Erdmann Nadia Haj Mohammad Lara R. Heij Heinz‐Josef Klümpen Eric T.T.L. Tjwa Liselot Valkenburg‐van Iersel Joanne Verheij Bas Groot Koerkamp Pim B. Olthof

Perihilar cholangiocarcinoma (pCCA) is a rare tumour that requires complex multidisciplinary management. All known data are almost exclusively derived from expert centres. This study aimed to analyse the outcomes of patients with pCCA in nationwide cohort.Data on all diagnosed Netherlands between 2010 and 2018 were obtained Cancer Registry. Data included type hospital diagnosis received treatment. Outcomes treatment overall survival.A total 2031 median survival for cohort was 5.2 (95% CI...

10.1111/liv.14856 article EN cc-by-nc Liver International 2021-02-28
 Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.
OPENALEX - Publications 
Yelena Y. Janjigian Do‐Youn Oh Sun Young Rha Keun Wook Lee Neeltje Steeghs and 9 more Yee Chao Maria Di Bartolomeo M. Díez García Nadia Haj Mohammad Alexander Stein William McAdoo Megan Winter Liz Croydon Jeeyun Lee

295 Background: T-DXd is an antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody, tetrapeptide-based cleavable linker, and topoisomerase I inhibitor payload. approved for HER2+ advanced/metastatic GC/GEJA after prior trastuzumab-based regimen (US/Israel) GC chemotherapy (Japan). In DESTINY-Gastric01, showed improved efficacy vs standard in Japanese Korean pts (≥2 therapies) with advanced GC/GEJA. Preclinical data combinations suggest encouraging antitumor activity....

10.1200/jco.2022.40.4_suppl.295 article EN Journal of Clinical Oncology 2022-01-19
 Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial.
OPENALEX - Publications 
Stijn Franssen Merve Rousian Lynn E. Nooijen B. Ten Haaft Michael Doukas and 8 more Nadia Haj Mohammad Heinz‐Josef Klümpen Adriaan Moelker Bianca Mostert Jeroen Hagendoorn Rutger‐Jan Swijnenburg Marjolein Y.V. Homs Bas Groot Koerkamp

433 Background: In the ABC-trials, 3-year overall survival (OS) was only 2.8% for patients with advanced intrahepatic cholangiocarcinoma (iCCA) confined to liver who received systemic gemcitabine cisplatin. Hepatic arterial infusion pump (HAIP) combined chemotherapy had a pooled OS of 39.5% in recent meta-analysis. HAIP involves continuous administration floxuridine (FUDR) directly into hepatic artery using subcutaneous pump. The aim this study prospectively assess effectiveness iCCA...

10.1200/jco.2024.42.3_suppl.433 article EN Journal of Clinical Oncology 2024-01-20
 Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands
OPENALEX - Publications 
Tara M. Mackay Anouk E.J. Latenstein Simone Augustinus Lydia G. van der Geest Auke Bogte and 60 more Bert A. Bonsing Geert A. Cirkel Lieke Hol Olivier R. Busch Marcel den Dulk Lydi M.J.W. van Driel Sebastiaan Festen Derk‐Jan A. de Groot Jan‐Willem B. de Groot Bas Groot Koerkamp Nadia Haj Mohammad Joyce T. Haver Erwin van der Harst Ignace H. J. T. de Hingh Marjolein Y.V. Homs Maartje Los Saskia Luelmo Vincent E. de Meijer Leonie J. Mekenkamp I. Quintus Molenaar Gijs A. Patijn Rutger Quispel Tessa E H Römkens Hjalmar C. van Santvoort Martijn W.J. Stommel Niels G. Venneman Robert C. Verdonk Frederike G.I. van Vilsteren Judith de Vos‐Geelen C. Henri van Werkhoven Jeanin E. van Hooft Casper H.J. van Eijck Johanna W. Wilmink Hanneke W.M. van Laarhoven Marc G. Besselink Hendrik Bos K. Bosscha Lodewijk A.A. Brosens Geert‐Jan Creemers Wouter L. Curvers Sarah Derks Susan van Dieren Erwin J. M. van Geenen Brigitte C.M. Haberkorn Gerrit J. Hemmink Chantal Hoge Akin Inderson Maarten Jacobs Emile D. Kerver Mike S.L. Liem Hans Lubbinge Jennifer M. J. Schreinemakers Heidi Schut Tom Seerden Joanne Verheij Annelie Vulink Caroline Wientjes Fennie Wit Frank J. Wessels Babs M. Zonderhuis

Importance Implementation of new cancer treatment strategies as recommended by evidence-based guidelines is often slow and suboptimal. Objective To improve the implementation guideline-based best practices in Netherlands pancreatic care assess impact on survival. Design, setting, participants This multicenter, stepped-wedge cluster randomized trial compared enhanced with usual consecutive patients all stages cancer. It took place from May 22, 2018 through July 9, 2020. Data were analyzed...

10.1001/jamasurg.2023.7872 article EN cc-by JAMA Surgery 2024-02-14
Coming Soon ...